ArticleJournal for immunotherapy of cancer2025

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.

Ana Carneiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.